ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 19 of 67
УЖМБС 2020, 5(3): 151–157
Clinical Medicine

Characteristics of Redox Homeostasis Parameters in Cirrhotic Patients With Synthropic Comorbid Lesions depending on the Liver Cirrhosis Severity

Abrahamovych M. O.1, Abrahamovych O. O.1, Fayura O. P.1, Fayura L. R.2

The purpose of the study was to characterize the parameters of redox homeostasis in cirrhotic patients with syntropic comorbid lesions, depending on the liver cirrhosis severity. Material and methods. The study was conducted in two stages. 75 patients (23 females (30.7%), 52 males (68.3%) with the mean age of 47.2 ± 10.4 years were included in the randomized trial with the preliminary stratification by the presence of liver cirrhosis. All of them were hospitalized and treated at Lviv Regional Hepatology Center. All patients underwent the complex comprehensive clinical laboratory and instrumental examination of all organs and systems in accordance with the requirements of the modern medicine. To study the redox homeostasis, we determined the contents of catalase and thiobarbituric acid products, in particular malondialdehyde. After obtaining the results, we characterized the content of redox homeostasis parameters in patients with liver cirrhosis and syntropic comorbid lesions, depending on its severity. The received results were handled on a personal computer in programs Excel 2010, Statistica 6.0, RStudio v. 1.1.442 and R Commander v.2.4-4 using descriptive statistics. The results obtained in the case of normal distribution were presented as M ± σ, n (the number of patients examined in the group), in case of abnormal distribution it was Me [25,0%; 75.0%]. The difference was considered statistically significant if p <0.05. Results and discussion. The study showed that in patients with liver cirrhosis along with the increase in its severity according to the criteria of C. G. Child-R. N. Pugh, the content of malondialdehyde increases and the content of catalase decreases in the presence of syntropic lesions of the digestive system, such as varicose veins of the esophagus, cirrhotic gastropathy, varicose hemorrhoidal veins; cardiovascular system: cirrhotic cardiomyopathy, heart rhythm disorders, arterial hypotension; respiratory system: hepatopulmonary syndrome; urinary system: hepatorenal syndrome; nervous system: hepatic encephalopathy; osteoarticular system: osteoporosis; hematopoietic system: anemia, coagulopathy; lesions of the skin, its appendages and mucous membranes. Conclusion. There is significance between the parameters of the pro- and antioxidant system and the cirrhosis severity in patients with liver cirrhosis and syntropic comorbid lesions, obtained according to the criteria of C. G. Child-R. N. Pugh (malondialdehyde content increase and catalase level decrease), which suggests their causal relationship.

Keywords: liver cirrhosis, redox homeostasis, reactive oxygen species, comorbid lesions, syntropy

Full text: PDF (Ukr) 222K

  1. Abrahamovych MO, Abrahamovych OO, Faiura OP, Tolopko SY, Ferko MR. Umist deiakykh endoteliizalezhnykh vazoaktyvnykh substantsii u krovi khvorykh zalezhno vid tiazhkosti tsyrozu pechinky ta stanu redoks-systemy organizmu. Lvivskyi klinichnyi visnyk. 2019; 4(28): 18-27. [Ukrainian].
  2. Abrahamovych MO, Abrahamovych OO. Klasyfikatsiia tsyrozu pechinky: retrospektyvnyi pohliad na problemu ta suchasne yii vyrishennia z urakhuvanniam syntropichnykh ko- ta polimorbidnykh urazhen khvoroho. Medytsyna transportu Ukrainy. 2013; 2: 10-6. [Ukrainian]
  3. Abrahamovych O, Abrahamovych M, Tolopko S, Fayura O, Ferko M. Character and Frequency of the Variations of Co- and Polymorbid Syntropic Extrahepatic Lesions and Their Dependence on the Hepatopulmonary Syndrome Severity Degree in Cirrhotic Patients. Georgian Medical News. 2016; 1(260): 34-41.
  4. Alexander V, Ivanov O, Khomich А, Birke B. Oxidative Stress in Hepatitis C Infection. The Liver. Oxid Stress Diet Antioxidants. 2018: 1-13.
  5. Assimakopoulos SF, Gogos C, Lambropoulou-Karatza C. Could antioxidants be the "magic pill" for cirrhosis-related complications? A pathophysiological appraisal. Med Hypotheses. 2011; 77: 419-23.
  6. Fujita N, Sugimoto R, Ma N, Tanaka H, Iwasa M, Kobayashi Y, et al. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat. 2008; 15(7), 498-507.
  7. Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol. 2018; 24(47): 5297-311.
  8. Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med. 2009; 47: 469-84.
  9. Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol. 2010; 53(5): 976-80.
  10. Xu XM, Zhou XY, Li XY, Guo J, Wang HZ, Li Y, et al. Increased oxidative damage of RNA in liver injury caused by hepatitis B virus (HBV) infection. Free Radic Res. 2018; 52(4): 426-33.
  11. Zampino R, Marrone A, Rinaldi L, Guerrera B, Nevola R, Boemio A, et al. Endotoxinemia contributes to steatosis, insulin resistance and atherosclerosis in chronic hepatitis C: the role of pro-inflammatory cytokines and oxidative stress. Infection. 2018; 46(6): 793-9.
  12. Zhou C, Lai Y, Huang P, Xie L, Lin H, Zhou Z, et al. Naringin attenuates alcoholic liver injury by reducing lipid accumulation and oxidative stress. Life Sci. 2019; 216: 305-12.
  13. Tymyrbulatov RR, Seleznev EY. Metod povyshenyia yntensyvnosty svobodnoradykalnoho okyslenyia lypydosoderzhashchykh komponentov krovy y eho dyahnostycheskoe znachenye. Lab delo. 1981; 4: 209-11. {Russian]
  14. Koroliuk MA, Ivanova LY, Maiorova YH, Tokarev VE. Metod opredelenyia aktyvnosty katalazy. Laboratornoe delo. 1983; 10: 16-8. [Russian]
  15. Dalle-Donne I, Rossi R, Colombo R, Gustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006; 52: 601-23.
  16. Boueiz A, Hassoun PM. Regulation of endothelial barrier function by reactive oxygen and nitrogen species. Microvasc Res. 2009; 77: 26-34.
  17. Federico А, Conti V, Russomanno G, Dallio M. A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. In Vivo. 2017; 31(4): 609-18.
  18. Ishikawa T, Seki S. The association between oxidative stress and endothelial dysfunction in early childhood patients with Kawasaki disease. BMC Cardiovasc Disord. 2018 Feb 9; 18(1): 30.
  19. Luu AZ, Chowdhury B, Al-Omran M Teoh H, Hess DA, Verma S. Role of Endothelium in Doxorubicin-Induced Cardiomyopathy. Send to Microcirculation. 2018; 25(7): e12486.
  20. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, et al. The Role of Oxidative Stress and Antioxidants in Liver Diseases. Int J Mol Sci. 2015; 16: 26087-124.
  21. Shrestha B, Prasai PK, Kaskas AM, Khanna A, Letchuman V, Letchuman S, et al. Differential arterial and venous endothelial redox responses to oxidative stress. Microcirculation. 2018; 25(7): e12486.
  22. Kim CH, Zou YN, Kim DH, Kim ND, Yu BP, Chung HY. Proteomic analysis of nitrated and 4-hydroxy-2-nonenal modified serum proteins during aging. J Gerontol A BiolSci Med Sci. 2006; 61: 332-8.
  23. Moreau R, Nguyen BT, Doneanu CE, Hagen TM. Reversal by aminoguanidine of the age-related increase in glycoxidation and lipoxidation in the cardiovascular system of Fischer 344 rats. Biochem Pharmacol. 2005; 69: 29-40.
  24. Diesen DL, Kuo PC. Nitric oxide and redox regulation in the liver: Part II. Redox biology in pathologic hepatocytes and implications for intervention. J Surg Res. 2011; 167: 96-112.
  25. Cichoz-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014; 20: 8082-91.
  26. Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K. Progression of alcoholic and non-alcoholic steatohepatitis: Common metabolic aspects of innate immune system and oxidative stress. Drug Metab Pharmacokinet. 2011; 26: 30-46.
  27. Wu D, Cederbaum AI. Oxidative stress and alcoholic liver disease. Semin Liver Dis. 2009; 29: 141-54.
  28. Iwakiri Y. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension. J Clin Gastroenterol. 2007; 41(10, Suppl 3): S288-94.
  29. Sessa WC. eNOS at a glance. J Cell Sci. 2004; 117(Pt 12): 2427-9.
  30. Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. Journal of Clinical Investigation. 1997; 100(11): 2923-30.
  31. Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999; 117(5): 1222-8.